Neurocrine Biosciences
NBIX
NBIX
590 hedge funds and large institutions have $12.9B invested in Neurocrine Biosciences in 2024 Q2 according to their latest regulatory filings, with 79 funds opening new positions, 251 increasing their positions, 188 reducing their positions, and 67 closing their positions.
New
Increased
Maintained
Reduced
Closed
Holders
590
Holders Change
+5
Holders Change %
+0.85%
% of All Funds
8.58%
Holding in Top 10
8
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-11.11%
% of All Funds
0.12%
New
79
Increased
251
Reduced
188
Closed
67
Calls
$125M
Puts
$53.6M
Net Calls
+$71.8M
Net Calls Change
+$45.4M
Top Buyers
| 1 |
State Street
Boston,
Massachusetts
|
+$85.1M |
| 2 |
Caisse de Depot et Placement du Quebec (CDPQ)
Montreal,
Quebec, Canada
|
+$69.4M |
| 3 |
1832 Asset Management
Toronto,
Ontario, Canada
|
+$69.4M |
| 4 |
AllianceBernstein
Nashville,
Tennessee
|
+$63.6M |
| 5 |
BlackRock
New York
|
+$59.2M |
Top Sellers
| 1 |
Point72 Asset Management
Stamford,
Connecticut
|
-$115M |
| 2 |
VPC
Vestal Point Capital
New York
|
-$97.9M |
| 3 |
Morgan Stanley
New York
|
-$71.7M |
| 4 |
Janus Henderson Group
London,
United Kingdom
|
-$56.1M |
| 5 |
Lord, Abbett & Co
Jersey City,
New Jersey
|
-$49.1M |
